SCHEMBL8320389

SCHEMBL8320389

Brc1cnc2[nH]cc(-c3cn[nH]c3)c2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 4/20 0.66
JAK2 O60674 3/20 0.66
MAPK8 P45983 2/20 0.66
AURKA O14965 2/20 0.66
AURKB Q96GD4 2/20 0.66
ROCK2 O75116 2/20 0.66
PLK4 O00444 1/20 0.66
PRKD3 O94806 1/20 0.66
MAP4K4 O95819 1/20 0.66
PRKCG P05129 1/20 0.66
INSR P06213 1/20 0.66
CDK1 P06493 1/20 0.66
FES P07332 1/20 0.66
IGF1R P08069 1/20 0.66
ROS1 P08922 1/20 0.66
FGFR1 P11362 1/20 0.66
PHKG2 P15735 1/20 0.66
FER P16591 1/20 0.66
FLT1 P17948 1/20 0.66
CDK2 P24941 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3351160 0.81 MAPK8 (0.56) DYRK1AMAPK8AURKAAURKBCLK2
SCHEMBL3349599 0.81 MAPK8 (0.56) DYRK1AMAPK8AURKAAURKBMAPK9
SCHEMBL1516750 0.79 JAK2 (1.00) DYRK1AJAK2MAPK8AURKAAURKB
SCHEMBL3351151 0.79 MAPK8 (0.57) DYRK1AMAPK8MAPK9MAPK10CLK1
SCHEMBL28614283 0.78 JAK2 (0.75) DYRK1AJAK2MAPK8AURKAAURKB
SCHEMBL1516629 0.77 DYRK1A (0.73) DYRK1AJAK2MAPK8AURKAAURKB
SCHEMBL8442334 0.77 AXL (0.54) DYRK1AMAPK8AURKAAURKBROCK2
SCHEMBL28610224 0.77 DYRK1A (0.68) DYRK1AJAK2MAPK8AURKAAURKB
SCHEMBL27729491 0.76 HTR1A (0.52) CDK1IGF1RFLT1FLT4KDR
SCHEMBL1516733 0.76 DYRK1A (0.67) DYRK1AJAK2MAPK8AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150183781-A1 5-(1H-Pyrazol-4-yl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors Um Pharmauji Sdn. Bhd. (MY) 2015-07-02 US disclosed
EP-2882748-A1 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS Aurigene Discovery Technologies Limited (IN) 2015-06-17 EP disclosed
WO-2014024077-A1 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-02-13 WO disclosed
WO-2004078756-A2 JNK INHIBITORS EISAI CO., LTD. (JP) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150183781-A1 5-(1H-Pyrazol-4-yl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors MAP3K1, MAP3K5, MAP3K3 DYRK1A 376/4885JAK2 241/4885MAPK8 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.